Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Aims to become India’s leading cancer testing company
Reaffirms Lupin’s commitment to sustainable resource management
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
Subscribe To Our Newsletter & Stay Updated